|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Graft Rejection | |||||
| Kidney Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Kidney Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Campath-1H | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Alemtuzumab | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |||||